Publications

Carreira B, Acúrcio RC, Matos AI, Moura LIF, Afonso MB, Viana AS, Santos FMF, Gois PMP, Rodrigues CMP, Guedes RC, Satchi-Fainaro R*, Florindo HF*, Polymeric-based neoantigen nanovaccine synergizes with PD-1/PD-L1 modulators, reprogramming the melanoma microenvironment, Journal of Controlled Release, 114178 (2025). *Corresponding authors. [ PUBMED ]

Koshrovski-Michael S, Rodriguez Ajamil D, Dey P, Kleiner R, Tevet S, Epshtein Y, Green Buzhor M, Khoury R, Pozzi S, Shenbach-Koltin G, Yeini E, Woythe L, Blau R, Scomparin A, Barshack I, Florindo HF, Lazar S, Albertazzi L, Amir RJ, Satchi-Fainaro R, Two-in-One Nanoparticle Platform Induces a Strong Therapeutic Effect of Targeted Therapies in P-selectin-expressing Cancers, Science Advances, 4762 (2024). [ PUBMED ]

Acúrcio RC*, Kleiner R*, Vaskovich-Koubi D*, Carreira B, Liubomirski Y, Palma C, Yeheskel A, Yeini E, Viana AS, Ferreira V, Araújo C, Mor M, Freund NT, Bacharach E, Gonçalves J, Toister-Achituv M, Fabregue M, Matthieu S, Guerry C, Zarubica A, Aviel-Ronen S, Florindo HF, Satchi-Fainaro R, Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy, Advanced Science, 202404159 (2024). *Corresponding authors. [ PUBMED ]

Peres C, Matos AI, Moura LIF, Carreira B, Verdial M, Conniot J, Afonso MB, Acúrcio R, Basto AP, Mensurado S, Silva-Santos B, Santos SCR, Viana AS, Silva LS, Rodrigues CMP, Préat V, Graça L, Madi A, Satchi-Fainaro R*, Florindo HF*. Multifunctional nanovaccine sensitizes triple-negative breast cancer to immune checkpoint therapy, Advanced Functional Materials, in press (2024). *Corresponding authors. [ PUBMED ]

Matos AI, Peres C, Carreira B, Moura L, Acúrcio R, Coelho R, Vogel T, Wegener E, Ribeiro F, Afonso M, Martínez-Barriocanal A, Arango D, Viana AS, Rodrigues C, Graça L, Jordan R, Satchi-Fainaro R*, Florindo HF*, Polyoxazoline-based nanovaccine and tumor-associated macrophage targeting sensitize colorectal cancer to anti-PD-1 immunotherapy, Advanced Science, 2300299 (2023). *Corresponding authors. [ PUBMED ]

Peres C, Matos AI, Moura LIF, Acúrcio RC, Carreira B, Pozzi S, Vaskovich-Koubi D, Kleiner R, Satchi-Fainaro R*, Florindo HF*, Preclinical models and technologies to advance nanovaccine development, Advanced Drug Delivery Reviews, 172:148-182 (2021). *Corresponding authors. [ PUBMED ]

Carreira B, Acúrcio RC, Matos AI, Peres C, Pozzi S, Vaskovich-Koubi D, Kleiner R, Bento M, Satchi-Fainaro R*, Florindo HF*. Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics; 2000147 (2020). [ PUBMED ]

Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini Y, Tiram G, Liubomirski Y, Satchi-Fainaro R. Immune-mediated approaches against COVID-19. Nature Nanotechnology, Jul 13:1-16 (2020).[ PUBMED ]

Conniot J, Scomparin A, Yeini E, Zupančič E, Peres C, Viana AS, Schwartz H, Erez N, Jung S, Satchi-Fainaro R*, Florindo HF*. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nature Nanotechnology;14(9):891-901 (2019). [ PUBMED ]

Florindo HF, Madi A, Satchi-Fainaro R. Challenges in the implementation of MIRIBEL criteria on nanobiomed manuscripts. Nature Nanotechnology;14:627-628 (2019). [ PUBMED ]
Matos AI, Carreira B, Peres C, Moura LIF, Conniot J, Fourniols T, Scomparin A, Martínez-Barriocanal Á, Arango D, Conde JP, Préat V, Satchi-Fainaro R*, Florindo HF*. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release; 10(307):108-138 (2019). [ PUBMED ]

Silva AL, Peres C, Conniot J, Matos AI, Moura L, Carreira B, Sainz V, Scomparin A, Satchi-Fainaro R, Préat V, Florindo HF. Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation. Seminars in Immunology; 34:3-24 (2017). [ PUBMED ]